JenaValve Technology, Inc.’s Post

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN™* platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3wymm4S Risk Info: https://bit.ly/4aatMct TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial 1-year outcomes uncover that Evolut™ #TAVR delivers superior valve performance vs. SAPIEN platform in women with small annuli.¹ Explore the evidence: https://bit.ly/3J8N9HF Risk Info: https://bit.ly/3Jbw1kK TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

We are pleased to announce the start of the JENA-VAD Registry, to evaluate the performance of the Trilogy valve in LVAD patients with significant AR. 📄 Read the full press release to learn more: https://lnkd.in/gWDfCUBj

AR is common in LVAD patients and most are at high operative risk. Without treatment, AR will lead to HF, leading to rehospitalization and mortality. This is an important study exploring the feasibility of TAVR for these patients. Truly an unmet need - and a reflection of the company's focus on patients.

Did you know? Once impacted by severe #AorticStenosis, women suffer from higher mortality than men, even after matching for age.¹ With the #SMARTtrial, we now know that women with small annuli who are treated with Evolut™ #TAVR experience superior valve performance at 1 year vs. SAPIEN platform.² Explore the evidence: https://bit.ly/43YzufX Risk Info: https://bit.ly/3W19YoE TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1 . Tribouilly C, et al. J Am Heart Assco. 2021;10:e018816. 2. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/3w6d6oI Risk Info: https://bit.ly/44rllbl TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance. Valve choice makes a difference. The Evolut™ #TAVR system has a unique design that enables greater blood flow and improved outcomes compared to SAPIEN platform at 1 year.¹ Explore the evidence: https://bit.ly/442CAja #AorticStenosis #SMARTtrial Risk Info: https://bit.ly/4cSqvB4 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

The CALIPSO Trial was presented at #EuroPCR comparing OCT-guided PCI vs angio-guided PCI in complex calcified lesions. Results: ✅ OCT-guided PCI was superior to angiography with greater MSA and with no difference in contrast usage & procedure time. Achieving optimal stent expansion (MSA area ≥ 90%) is proven to reduce rates of adverse cardiac events. Stent underexpansion is an indicator of adverse events, such as stent thrombosis & restenosis as concluded by Raber et al: https://bit.ly/RaberECD How can Abbott Help? Ultreon Software, enabled by AI, provides automatic calcium detection & its severity—calcium arc, length and thickness—helping you plan a proper lesion prep & treatment approach. Get started today: www.Ultreon.com Important Safety Info: http://bit.ly/OCT_ISI

The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/43NEsw2 Risk Info: https://bit.ly/4aKWBwY TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.

How is the Trilogy System unique from other TAVR devices? Check out this interview for a very nice overview of TAVR for AR. 💡